scholarly journals Gabapentin Enacarbil Extended‐Release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial

2020 ◽  
Vol 44 (9) ◽  
pp. 1875-1884
Author(s):  
Eugene M. Laska ◽  
Carole E. Siegel ◽  
Ziqiang Lin ◽  
Michael Bogenschutz ◽  
Charles R. Marmar
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Extended Release ◽  
Gabapentin Enacarbil

scholarly journals Risk of Relapse Among Opioid‐Dependent Patients Treated With Extended‐Release Naltrexone or Buprenorphine‐Naloxone: A Randomized Clinical Trial

2021 ◽  
Vol 30 (5) ◽  
pp. 453-460
Author(s):  
Arild Opheim ◽  
Zhanna Gaulen ◽  
Kristin Klemmetsby Solli ◽  
Zill‐e‐Huma Latif ◽  
Lars T. Fadnes ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Extended Release ◽  
Risk Of Relapse

scholarly journals Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens

2020 ◽  
Vol 29 (4) ◽  
pp. 313-322 ◽  
Author(s):  
Sandra D. Comer ◽  
Paolo Mannelli ◽  
Danesh Alam ◽  
Antoine Douaihy ◽  
Narinder Nangia ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Extended Release ◽  
Opioid Use Disorder ◽  
Opioid Use

New Drug Review: Gabapentin enacarbil extended release (Horizant™) – A new formulation on the horizon

2011 ◽  
Vol 1 (6) ◽  
pp. 128-130
Author(s):  
Amy B. Werremeyer
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Extended Release ◽  
Gabapentin Enacarbil ◽  
New Drug ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
New Formulation ◽  
Trial Evidence ◽  
Drug Review

Gabapentin enacarbil was approved by the Food and Drug Administration (FDA) in April of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

scholarly journals Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial

2019 ◽  
Vol 25 (6) ◽  
pp. 303-309
Author(s):  
Kristin Klemmetsby Solli ◽  
Nikolaj Kunoe ◽  
Zill-E-Huma Latif ◽  
Kamni Sharma-Haase ◽  
Arild Opheim ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Extended Release
Sign in / Sign up

Export Citation Format

Share Document